Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Arunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, +13

The Lancet

VaccinationVaccine SafetyVaccinologyProtective EfficacyThai Schoolchildren +6

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

Shibadas Biswal, Humberto Reynales, Xavier Sáez‐Llorens, +20

New England Journal of Medicine

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas, +66

The Lancet

VaccinationVaccine SafetyPediatricsVaccine TrialVaccine Efficacy +3

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Luis Rivera, Shibadas Biswal, Xavier Sáez‐Llorens, +27

Clinical Infectious Diseases

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Vianney Tricou, Delia Yu, Humberto Reynales, +29

The Lancet Global Health

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial

Vianney Tricou, Xavier Sáez‐Llorens, Delia Yu, +16

The Lancet

VaccinationVaccine SafetyVaccinologyVaccine DevelopmentVaccine Testing +4

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

Eduardo López‐Medina, Shibadas Biswal, Xavier Sáez‐Llorens, +27

The Journal of Infectious Diseases

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study

Xavier Sáez‐Llorens, Vianney Tricou, Delia Yu, +5

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccinologyPreventive MedicineVaccine Development +10

Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study

Chukiat Sirivichayakul, Elizabeth A Barranco-Santana, Inés Esquilin-Rivera, +10

The Journal of Infectious Diseases

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

Xavier Sáez‐Llorens, Vianney Tricou, Delia Yu, +11

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccinologyGlobal HealthVaccine Surveillance +10